Results 1 to 6 of 6
Page 1 of 1
TypeTitleAuthor(s)YearViews
A phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC)Yau, TCC; Sukeepaisarnjaroen, W; Chao, Y; Yen, CJ; Lausoontornsiri, W; Chen, PJ; Sanpajit, T; Lencioni, R; Camp, AC; Cox, DS; Kallender, H; Ottesen, LH; Poon, RTP201249
 
Is the treatment of hepatocellular carcinoma on the waiting list necessary?Majno, P; Lencioni, R; Mornex, F; Girard, N; Poon, RT; Cherqui, D2011227
 
A phase I/II study of Foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2 and VEGFR in advanced hepatocellular carcinoma (HCC)Yau, TCC; Sukeepaisarnjaroen, W; Chao, Y; Yen, CJ; Lausoontornsiri, W; Chen, PJ; Sanpajit, T; Lencioni, R; Camp, A; Kallender, H; Ottesen, LH; Poon, RTP2011117
 
A Phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2 and VEGFR in advanced hepatocellular carcinoma (HCC)Yau, T; Yen, CJ; Chen, PJ; Chau, Y; Lencioni, R; Kallender, H; Ottesen, LH; Poon, RTP2011252
 
Treatment before liver transplantation for HCCBelghiti, J; Carr, BI; Greig, PD; Lencioni, R; Poon, RT2008136
 
Phase 3, randomized, double-blind, dummy-controlled, trial of radiofrequency ablation (RFA) + lyso-thermosensitive liposomal doxorubicin (LTLD, Thermodox), for hepatocellular carcinoma (HCC) lesions 3-7 cmTak, WY; Lin, SM; Wang, Y; Zheng, J; Izzo, F; Park, SY; Chen, MH; Wong, SN; Xu, R; Peng, CY; Chiou, YY; Huang, GT; Lee, JY; Sherman, M; Abdullah, BJJ; Lee, JS; Wang, JH; Borys, N; Poon, RTP; Lencioni, R-35
 
Page 1 of 1
Export Records
Step 1: Select content and export format
  • Citation only
Step 2: Select export method
  • Download